This method leverages the fact that many pathogens, or their genetic material, are shed by infected individuals (even those who are asymptomatic) into the wastewater system through feces, urine, or other bodily fluids.

How Wastewater Surveillance Works

1. Shedding of Pathogens: Individuals infected with certain viruses or bacteria—such as SARS-CoV-2 (the virus causing COVID-19), influenza, RSV, or even poliovirus—shed genetic material (DNA or RNA) or whole pathogens into their bodily waste. This shedding can occur even before symptoms appear or in individuals who never develop symptoms, making it a valuable early indicator.
2. Collection of Wastewater Samples: Wastewater utilities collect samples of untreated municipal wastewater from various points within the sewer system, typically at wastewater treatment plants. These samples represent a pooled aggregate of waste from thousands, or even millions, of people connected to that specific sewershed (the geographic area served by a particular sewer system).
3. Laboratory Analysis: The collected wastewater samples are transported to laboratories for analysis. Advanced molecular techniques, primarily quantitative polymerase chain reaction (qPCR) and genomic sequencing, are used to detect and quantify the presence of specific pathogen genetic material.
   • qPCR: This method amplifies specific DNA or RNA sequences, allowing scientists to determine the concentration of a pathogen in the sample. Higher concentrations generally indicate more widespread infection in the community.
   • Genomic Sequencing: This goes a step further, allowing researchers to identify specific variants or strains of a pathogen (e.g., new SARS-CoV-2 variants or, as in the North Carolina case, a specific clade of mpox) and track their prevalence.
4. Data Interpretation and Public Health Action: The laboratory results are then analyzed and interpreted by public health officials. This information helps them:
   • Detect Early Trends: Wastewater data can show increases or decreases in disease trends days to weeks before they are observed through clinical testing or healthcare visits. This is particularly crucial for asymptomatic cases that might not seek medical care.
   • Complement Clinical Data: WBE provides a community-level snapshot, independent of individual testing behaviors, healthcare access, or testing availability. It complements clinical surveillance data, offering a more complete picture of disease spread.
   • Predict Outbreaks and Inform Response: By monitoring changes in pathogen concentrations and identifying emerging variants, public health officials can anticipate potential outbreaks, allocate resources (e.g., testing sites, vaccination campaigns), and implement targeted public health interventions (e.g., public health messaging, mask mandates).
   • Monitor Antimicrobial Resistance: Wastewater can also be analyzed for the presence of antibiotic-resistant genes, providing insights into antimicrobial resistance trends within a community.

Credible Articles and Key Insights

• Centers for Disease Control and Prevention (CDC) National Wastewater Surveillance System (NWSS): The CDC has been instrumental in establishing and promoting wastewater surveillance, especially during the COVID-19 pandemic. Their website provides comprehensive information on how WBE works, current data for various pathogens (COVID-19, influenza, RSV, mpox), and its role in public health. They highlight that wastewater data can provide “early indications of changes in community levels of SARS-CoV-2, as well as emerging variants of the virus, sometimes weeks ahead of other public health data.”
  • Reference: https://www.cdc.gov/nwss/how-wws-works.html
• North Carolina Department of Health and Human Services (NCDHHS) Press Release on Mpox Detection: The NCDHHS issued a press release on April 22, 2025, detailing the detection of Clade I mpox viral particles in wastewater samples in Greenville, NC. This was particularly significant as Clade I mpox had not been previously reported in North Carolina, demonstrating wastewater surveillance’s ability to identify the presence of a pathogen before clinical cases are confirmed.
  • Reference: https://www.ncdhhs.gov/news/press-releases/2025/04/22/mpox-found-wastewater-north-carolina-ncdhhs-urges-public-and-providers-be-alert
• National Academies of Sciences, Engineering, and Medicine Reports: Reports commissioned by the CDC, such as “Wastewater-based Disease Surveillance for Public Health Action,” provide in-depth analysis of the benefits, challenges, and future of WBE. They emphasize its value beyond COVID-19 for various infectious diseases and its ability to capture pre-symptomatic and asymptomatic cases.
  • Reference: https://www.ncbi.nlm.nih.gov/books/NBK591714/
• “Wastewater surveillance as a sentinel for disease” (UNEP): This article highlights that wastewater sampling has been used for a long time to detect diseases like polio and has expanded significantly since COVID-19. It emphasizes WBE’s ability to “cost-effectively gauge the extent to which a disease might be circulating in a community, without solely relying on data from people using health services.”
  • Reference: https://www.unep.org/technical-highlight/wastewater-surveillance-sentinel-disease
• “Wastewater-based epidemiology as surveillance and early warning of infectious disease outbreaks” (ResearchGate/PubMed): Several review articles delve into the potential of WBE as an early warning system. They emphasize that “the biological principle underlying wastewater as a leading indicator is that many infected individuals excrete the virus in biological samples before they develop symptoms, and thus before seeking medical care.”
  • Reference: https://www.researchgate.net/publication/341300170_Wastewater-based_epidemiology_as_surveillance_and_early_warning_of_infectious_disease_outbreaks
  • Reference: https://pubmed.ncbi.nlm.nih.gov/32395676/
• “Advances in Wastewater-Based Epidemiology for Pandemic Surveillance: Methodological Frameworks and Future Perspectives” (MDPI): This recent review underscores WBE’s role in “transforming pandemic surveillance from reactive containment to proactive population health management.” It discusses advancements in pathogen detection technologies (qPCR and metagenomics) and predictive modeling.
  • Reference: https://www.mdpi.com/2076-2607/13/5/1169

Key Advantages for Outbreak Prediction

• Early Detection: Pathogen shedding can occur before clinical symptoms, allowing for earlier detection of increasing cases.
• Population-Level Data: Provides a broad overview of community infection trends without relying on individual testing or healthcare-seeking behavior.
• Detection of Asymptomatic Cases: Captures infections in individuals who may never get tested or seek medical care.
• Identification of Variants: Genomic sequencing allows for tracking of emerging and circulating variants of concern.
• Cost-Effective and Efficient: A single sample can provide information for a large population, making it more efficient than widespread individual testing.
• Privacy-Preserving: It collects aggregate data, avoiding individual identification.

While wastewater surveillance is a powerful tool, it’s most effective when integrated with other public health surveillance systems to provide a comprehensive understanding of disease spread and inform public health decisions.

Maintaining visibility is essential. Today, with money for science companies tight, you might want to stay on the sidelines. Don’t. Strategic PR reports your milestones, builds credibility, and makes you stand out while everyone else is sitting out. Even announcements of future intentions serve to position your company within the industry. That’s why Carnivores has created an effective PR program that complements your operations and does not divert time and budget from core innovations.

Core Services for Every Release

Content Enhancement

The company knows the facts. Our science writers know how to finesse.

• Professional editing and formatting of your draft content
• Strategic headers, subheads, and properly formatted hyperlinks
• Featured key takeaways that highlight critical information

Visual Elements 

Graphics tell the story in new ways. That’s critical, and included in the price.

• 3-5 custom graphics designed to highlight key messages
• No additional fees for including visuals in your release
• Repurposable graphics for social media content

Supporting Information

The right mix of proof-points.

• Structured sidebar containing relevant background information
• Professional biographies and executive information
• Curated links to supporting materials (PDFs, videos, decks)

Performance 

Analytics and Benchmark Measurement

• Comprehensive tracking
• Publication location reporting
• Engagement statistics to measure impact

Two Simple Distribution Tiers

Tier 1: Standard Distribution Protocol

• Indexing on Google and other search engines
• News portal syndication
• All core services listed above

Tier 2: Enhanced Life Sciences Distribution Network

• Syndication to specialized life sciences outlets like BioSpace
• Custom query of our life sciences journalist database
• Personalized emails to the most relevant journalists
• Release synopsis sent directly to targeted media contacts
• Comprehensive tracking of email opens, shares, and link clicks

One More Thing: Flexibility

Not every one of your releases will be at the same level of importance. Our approach allows you to level up or down between Tier 1 and Tier 2 based on your announcement, to help scale costs and allow for more frequent news updates. Ask us how that works to your advantage.

Don’t Forget SEO 

Regular press releases provide a significant SEO advantage. Search engines favor websites with consistent, fresh content. Each release creates newly indexed pages, generates valuable backlinks, and expands your digital footprint with targeted keywords. This publishing cadence signals to Google that your company is active and authoritative, improving search rankings and enhancing discoverability for partners, investors, and customers. Even modest announcements contribute to cumulative SEO benefits that paid advertising cannot match.

We Hope You Will Consider Content Carnivores for Upcoming Communications and Press Releases

Content Carnivores has published over a thousand press releases for life sciences companies of all sizes. Our methodology is refined through empirical data into a streamlined system that preserves quality while eliminating inefficiencies. Clients work with category experts who understand scientific concepts, not sales representatives. We approach every project with genuine enthusiasm for science and a commitment to advancing our clients’ work through effective communication. We’d be happy to walk through our framework and pricing relevant to other services.

We look forward to discussing your upcoming news. 

Examples:

Pacylex Pharmaceuticals

Georgia BIO

GeoVax Labs

By Chelli Miller Biotech Lead Partner @ Content Carnivores |

We all say it, but it’s true: the drive behind life sciences innovation, the relentless pursuit of cures, is deeply personal. You don’t just work in this field; you invest your heart and soul. My connection to Pacylex Pharmaceuticals and the journey they’re on with AML is a perfect example of a rare intersection of the personal and the professional.

Professionally, this journey started with Pacylex’s CEO, Michael Weickert, Ph.D, someone I’ve known since the very beginning of my two decades in healthcare. I remember his work at Sea Medical, inspired by his family’s experience with extensive hospitalization of their new baby. His emotional personal experience, coupled with his scientific knowledge, helped make the Sea Medical story resonate with me. That same passion fueled Pacylex’s work on a novel approach to treating acute myeloid leukemia (AML), a particularly brutal cancer, especially for children.

AML, as I’ve come to understand it more deeply, is a cancer that affects the blood and bone marrow. It’s an aggressive disease where immature blood cells rapidly accumulate, hindering the production of normal blood cells. It’s particularly devastating in children. Pediatric AML, pediatric cancer in general, presents unique treatment challenges. Children’s bodies metabolize drugs differently than adults, making it difficult to adapt adult treatment protocols. AML in children can be especially aggressive, and relapse is a significant concern. Finding effective therapies for relapsed or refractory AML – when the cancer doesn’t respond to initial treatment – is a major hurdle. Even then, adults are treated first, and only when safety and efficacy is determined, would a child be treated with a new treatment modality. The harsh reality is that the toxicity of existing chemotherapies takes a greater toll on growing children. This is a huge reason we need novel therapies that can also treat our young!

Content Carnivores started working with Pacylex when they were in the preclinical stage. They were developing a completely new way to attack AML. Their lead drug, zelenirstat, is a first-in-class N-myristoyltransferase inhibitor (NMTI). It works by inhibiting myristoylation, a fatty acid modification crucial for certain proteins to function in cancer cell survival and proliferation. In simpler terms, zelenirstat targets key cancer-driving processes that depend on myristoylation, which kills cancer cells at drug levels that don’t harm normal cells. Think of it like this: Cancer cells use myristoylation to help them grow and spread. Zelenirstat is designed to stop that. It’s a novel approach, targeting the disease in ways other treatments don’t.

At about this time, life threw me a cruel curveball. A dear friend, someone I’ve known since I was practically a kid myself, called me. This was a friend whose family I adore – I even named my son after her daughter and son. She told me her 12-year-old granddaughter had been diagnosed with AML. As a new grandmother, myself, the news hit me like a ton of bricks.

My friends are a brilliant family living in the Chicago area. They assembled a team of researchers and experts, leaving no stone unturned. They fought tooth and nail to get their granddaughter into every treatment modality and clinical trial possible. We watched as her little body endured round after round of treatments, hoping against hope for a positive response.

A few devastating years passed for my friends, and Pacylex continued its work. I watched every avenue and every potential treatment be exhausted. Then, just before this beautiful girl’s 16th birthday, she, with heartbreaking grace and acceptance, planned her 16th birthday party or her funeral. There was nothing left to try. Her body was just too weak. I tear up just thinking about this!

And that’s where Pacylex’s work became even more significant to me. Their novel mechanism was something her body hadn’t encountered before. Preclinical studies suggested AML cells, including AML stem cells, are particularly sensitive to zelenirstat. It’s designed to trigger apoptosis and cell death in AML. But it was too late. She had run out of time. We attended her 16th birthday, which was also her funeral. That experience, that loss, is seared into my memory and my heart.

Personally, this child’s diagnosis and battle with AML created a powerful connection to my professional work with Pacylex. I wish that the treatments being developed by Pacylex Pharmaceuticals had been advanced to the point where she might have participated in their trials. This was a perfect case for a Compassionate Use Designation – an FDA designation that allows patients with serious or life-threatening conditions to access investigational drugs or medical devices outside of clinical trials when no other treatment options are available. Zelenirstat data continues to indicate the need for the designation for AML as well as other tumor types.

Fortunately, the company is advancing, meaning others like her will have a fighting chance against this devastating disease.

Today, Pacylex is making real progress. They have clinical data. A published Phase 1 dose escalation safety and tolerability study in 29 heavily pre-treated patients showed that zelenirstat was well-tolerated, with most adverse events being mild gastrointestinal side effects. The study also showed that zelenirstat prolonged cancer progression-free and overall survival in solid tumor patients receiving the recommended Phase 2 dose. They’re moving into Phase 2, and the results are promising.

I still see my friends on Facebook, still actively supporting other families battling AML, still organizing blood drives in their daughter’s name. It’s both heartbreaking and inspiring. Every time I see this, I am reminded of the family’s desperate quest to find trials, novel treatments—anything to help the medical team save their loved one.

This isn’t just a professional interest for me anymore. It’s deeply personal. It reinforces why we do what we do in healthcare. Cancer is personal. We all know someone who’s lost the battle, and we all know countless lives could be saved with the right innovation. We need multiple innovations because each body, at every age, is different.

I’m incredibly proud to be involved in getting the word out about Pacylex’s work. It’s more than just marketing and PR; it’s about advocating for the funding and support companies and families desperately need. We need to accelerate the pace and funding of innovation because every day counts. Every child, every parent, deserves a chance. And that’s why I’m here, telling this story, because it’s not just their story; it’s part of mine.

The Background

An ongoing dialogue between BioUtah and various UK trade organizations, including representatives of the British government, continues to strengthen ties between the two regions. Initiated by a 2023 Memorandum of Understanding focused on supporting biotech companies, these discussions have fostered a valuable connection. The program has been designed to create a flow of business ideas and relocations for companies looking to expand into the UK, or vice-versa. Content Carnivores partner, Chelli Miller, has been a part of the progress and has co-authored a proposal for leveraging clinical trials as a ‘first step’ in bringing the MoU to fruition.

The Twist

This burgeoning relationship recently led to a unique opportunity at the Sundance Film Festival. Content Carnivores, a BioUtah Member and a participant in these ongoing discussions, was invited by the UK/Wales Trade Association to film the premiere of “Brides,” which they helped fund. The Carnivores team, including their relationship with film company Rare Sightings, captured the excitement of the premiere at The Egyptian Theatre, the film’s after-party, and the vibrant energy on Main Street. This collaboration exemplifies the unexpected possibilities emerging from this transatlantic partnership. Stay tuned for future developments in the Life Sciences chapter of this evolving story! And the role that Content Carnivores plays in promoting global collaboration.

The Results

BRIDES at Sundance

A Changing of the Guard

Perhaps the most telling shift was in who didn’t show up. Many senior executives who responded to our survey bypassed the event, citing San Francisco’s ongoing urban challenges – a diplomatic way of expressing their frustration with the city’s visible struggles. However, their absence cleared the way for something unexpected: a new generation of healthcare professionals who energized the conference floors and meeting rooms.

These younger attendees, many experiencing the conference for the first time, tackled challenges without the weight of industry cynicism. Their social media posts and follow-up communications sparkled with enthusiasm about merging science, business, and global health impact. As one first-time attendee put it in a LinkedIn post, “This isn’t just about deals – it’s about seeing how our work could change lives across the globe.”

The Money Dance

While billion-dollar deal announcements from JPMorgan ignited early optimism, the real story unfolded beneath the headlines. A striking contrast emerged between bank analysts (who, as one participant quipped, “are paid to be pessimistic”) and the broader sense of possibility that energized most discussions.

The Funding Paradox

Yet beneath this optimistic surface, a more complex reality took shape. One biotech CEO, currently raising a $40 million Series C round, captured the moment perfectly: “People are interested in talking, but they’re not writing checks.” This sentiment echoes across the industry, where despite promising scientific advances and fast-track designations, capital remains stubbornly on the sidelines.

The reality cuts deep: companies with drugs in advanced human trials, even those with FDA fast-track or orphan disease designations, struggle to translate regulatory acceleration into funding momentum. Deal flow indicators across the sector continue to show stagnation or decline, a trend that has persisted for several years.

The funding challenge looms at every level: from seed-stage companies emerging from university tech transfer offices to established public companies managing shareholder expectations. Each competes for limited capital, often against similar technologies and approaches.

The Elephant in the Room

The Inflation Reduction Act (IRA) discussions sparked some of the conference’s most heated moments. When the topic surfaced – and it surfaced often – conversations transformed. Investment panels sometimes devolved into what one attendee dubbed “sophisticated venting sessions” about profit margins. Yet these debates seemed strangely disconnected from the conference’s broader spirit of innovation and possibility.

A More Nuanced View

The Squire Patton Boggs law firm’s evening session broke through the usual talking points, exploring how administrative changes could reshape healthcare delivery. Instead of fixating on bottom lines, speakers examined how policy shifts could transform clinical trial diversity and global health equity. The packed room and spirited discussion revealed an appetite for deeper, more nuanced conversations.

Beyond the Headlines

Veterans know that splashy deal announcements don’t always signal broader market momentum. Throughout the event, an interesting tension played out between market skepticism and innovation optimism.

The After Hours That Matter

Evening receptions proved crucial in fostering genuine connections. Major firms and organizations transformed typical networking events into vibrant forums for exchange. These gatherings – some welcoming upwards of 250 attendees – sparked conversations that couldn’t happen in formal sessions.

These hosts deserve special recognition. Their commitment to building community extended the conference’s impact well beyond official hours. Discussions meandered from scientific breakthroughs to personal missions, planting seeds for future collaborations.

A Balanced View Forward

The conference painted a complex picture of an industry in transition. Young healthcare professionals face the same fundamental challenge that has always defined this sector – bridging the gap between scientific promise and financial backing. There was a strong emergence of regional groups representing rapid growth outside of the usual Life Sciences hubs. For the first time, BioUtah sponsored the State BioTech reception, signaling the progress and commitment to this category.

Perhaps most encouraging was the shift in how participants measure success. While deals and dollars remain crucial, a new understanding emerged: healthcare’s future demands both profitability and purpose. As one young executive observed during an evening reception, “We’re not just here to make money – we’re here because we believe we can make a difference.”

The Reality Check

This idealistic drive exists within unyielding market constraints. The path from innovative science to funded company demands not just breakthrough ideas but endurance through years of fundraising challenges. As one veteran biotech CEO put it, “We remain optimistic because we have to be. The solutions we’re developing matter too much to give up.”

In general, the Carnivores leadership team will navigate the busy roads at this landmark healthcare intersection to facilitate awareness, meetings, and thought leadership.

On a community level, Carnivores principals will moderate company presentations at Biotech Showcase, presenting emerging and established companies to a global audience.

• We’re not alone in feeling optimistic about the life sciences in 2025. Our clients, colleagues and healthcare leaders welcome a neutral, if not favorable, investment climate after 2024’s headwinds.
• As deal flow improves, companies must maintain a cadence of compelling narratives that keep investors, partners, and stakeholders interested. This has proven the most cost-effective way to communicate the company’s vision, differentiation, and ‘reason for believing.’
• To prepare for upcoming outreach and/or capital raises, companies are advised to take a hard look at their websites and video communications to determine if the belt-tightening of the past couple of years has resulted in materials that are no longer up to date, or even reflective of the current mission.

Clients Taking Center Stage:

Content Carnivores is proud to support several clients who will be present at the conferences during JPM Week, including:

• BioUtah: The leading trade association for the life sciences industry in Utah. BioUtah will participate in hosting a Multi-State Reception on Sunday night, kicking off the week with networking opportunities alongside other state bioscience associations. This event marks BioUtah’s first year sponsoring a reception during JPM Week, demonstrating its commitment to the global life sciences community and the industry’s growth in Utah. BioUtah CEO Kelvyn Cullimore will be on hand to discuss and promote the state’s business-friendly environment and growing life sciences ecosystem.
• Colliers International: A global leader in commercial real estate with a growing focus on life sciences in Salt Lake City. Colliers will highlight the region’s burgeoning life sciences sector and its expanding need for specialized lab space, headquarters, and other facilities. Managing Partner Chris Kirk will represent the company and their expanded focus on science and technology companies. 
• GeoVax Labs: A clinical-stage biotechnology company developing next-generation vaccines for infectious diseases and cancer. GeoVax will present at Biotech Showcase, highlighting their recent $400 million BARDA grant for a 10,000-patient trial and, separately, updates on their progress with their head and neck cancer therapy.
• Geovax CEO David Dodd will present at Biotech Showcase on January 14, 2025, at 10:30 am PST at the Hilton Union Square, 333 O’Farrell Street, Yosemite A (Ballroom Level). 
• Pacylex Therapeutics: This exciting company, with its first-in-class therapy, zelenirstat, presents a compelling investment opportunity in the oncology space. Zelenirstat targets a novel pathway, potentially surpassing existing treatments in efficacy and tolerability. Pacylex CEO Michael Weickert is raising a Series B financing and is available to connect through the BIO partnering system.

Read the full release here. https://www-contentcarnivores-com.reportablenews.com/pr/contact-carnivores-celebrates-18-years-at-jp-morgan-healthcare-conference-and-biotech-showcase?_gl=1*1qdaws6*_gcl_au*OTA1MDczNjgyLjE3MzU4NTc4MzM.

The Problem:

Zacks Small Cap Research (SCR) provides in-depth research reports on a diverse range of emerging companies seeking capital, spanning sectors like mining, crypto, biotech, medtech, technology, blockchain, and more. While their analysts produce comprehensive, bank-style reports offering valuable insights into each company’s mission, vision, and market opportunity, their existing marketing strategy presented a challenge. Zacks SCR relied heavily on an outdated email marketing system with a static template, limiting their ability to:

• Drive website traffic: Their existing, limited email network had static results typical of the >1% open rate for investor-focused emails.
• Expand their reach: They drove people to a registration page to download reports–a practice that would have most investors wary of future spam (which was true).
• Maximize content impact: They had a one-and-done mentality for sending the email once the report was published.
• Keep Up: With dozens of reports published quarterly, and hundreds of companies to service, the Zacks team simply could not generate the right content in a timely manner.

The Opportunity

While this limited approach, coupled with a minimal social media presence, hindered Zacks SCR’s ability to maximize, it provided a unique insight. Because the existing email program, while outdated, still generated consistent traffic, it allowed visibility into a real-time benchmark against which to measure the effectiveness of a new content marketing strategy. In many cases the old program is changed, or discontinued. Continuing the old program might have been seen to cause branding problems. Read on to see how this opened other doors. 

The Content Carnivores Solution:

Content Carnivores was engaged to revitalize Zacks SCR’s marketing efforts and amplify the reach of their research. Recognizing the value of the existing email program as a benchmark, Content Carnivores implemented a multi-faceted strategy that complemented and expanded upon the existing efforts. This included:

• Content Repurposing: Transforming complex research reports into digestible and engaging social media content, featuring compelling headlines, key findings, and insightful data, tailored for a general audience.
• Multi-Platform Distribution: Strategically distributing content across major social media platforms like Facebook, Twitter, and LinkedIn to maximize visibility and reach a wider investor audience.
• Amplified Reach: Leveraging their own extensive network and continuously expanding the number of social outlets to ensure maximum content exposure.
• Video Integration: Incorporating video content creation to provide companies with a dynamic medium to tell their story and connect with investors on a deeper level.

Analysis and Results:

The results were compelling: Content Carnivores’ content-driven strategy delivered a 280% increase in website traffic compared to the outdated email marketing approach. This underscored the power of their multi-faceted strategy in attracting and engaging a wider audience. 

By running the existing email program concurrently with the Content Carnivores strategy, Zacks SCR gained the ability to conduct a real-time, head-to-head comparison of the two approaches. This provided invaluable data on the effectiveness of each strategy in driving website traffic and engaging potential investors.

When the CEO decided that the overall program was not impacting the companies covered with regards to increasing their share price, the program was paused. (Note: Content Carnivores programs are targeted to reach investors but never to solicit or encourage stock purchases or to impact the share price. That would be stock promotion. It’s illegal. We’re happy to get fired when the ‘ask’ has even the whiff of that kind of behavior.) 

The impact of pausing the Content Carnivores program further validated its effectiveness. Thanks!

After three years of build up the website traffic, engagement and demographics of the audience, the pause caused significant declines:

• Social referral traffic decreased by 44%, resulting in a loss of over 700 website visits.
• Organic traffic plummeted by over 74%, highlighting the program’s indirect impact on search engine visibility and leading to a loss of 6,000 website visits.
• Stocktwits referral traffic fell by 62%, indicating a significant drop in engagement from retail traders.

We are extremely grateful to have these stats.

In effect we have data from before the program, during the program, and then after the program was suspended. These findings emphasized the crucial role of consistent and engaging content marketing in driving website traffic, maintaining online presence, and reaching target audiences.

It’s Just Marketing, right?

The Zacks SCR case study exemplifies the transformative power of a dynamic and comprehensive content marketing strategy in driving investor engagement and amplifying the reach of valuable research. By leveraging content repurposing, multi-platform distribution, and targeted outreach, Content Carnivores enabled Zacks SCR to connect with a wider audience, maximize the impact of their research, and achieve measurable results. In the end, the ability to conduct a real-time comparison of before, after, and after, provides invaluable insights and further validated the effectiveness of the Content Carnivores approach.

For an entrepreneur, landing that Series A funding round is like reaching the summit of Everest. But what happens after the champagne toasts and the press releases fade? How does the company keep their story alive? That’s where the real climb begins, and for VCapital, a Chicago-based venture capital firm specializing in early-stage tech, biotech, and diagnostics companies, they knew they needed more than just a sherpa – they needed a guide.

VCapital, with its impressive track record of billion-dollar exits and a keen eye for “visionary” investments, had a challenge. Although it was a master of due diligence and deal-making, its brand presence was quiet, almost hidden. It needed a way to amplify its voice, attract investors to its growing fund, and showcase the groundbreaking work of its portfolio companies. Enter Content Carnivores.

Content Carnivores didn’t just offer VCapital a marketing plan; they provided a comprehensive content ecosystem. Think of it as a toolkit for the modern VC firm, packed with strategies to build a powerful brand and engage a targeted audience.

The Spearhead: Content that Cuts Through the Noise

Imagine explaining the intricacies of gene editing or the latest breakthrough in cancer diagnostics to a potential investor who’s more familiar with balance sheets than biopsies. Content Carnivores crafted a “spear content” strategy, translating complex science into compelling narratives that resonated with a wider audience. They didn’t dumb it down; they made it accessible, highlighting the human impact of these innovations.

The Megaphone: Amplifying Thought Leadership

VCapital’s CEO wasn’t just a seasoned investor but a thought leader with a book on the horizon and a growing media presence. Content Carnivores seized this opportunity, transforming him into the face of VCapital. They leveraged his insights and appearances to build credibility and position VCapital as an industry pioneer.

The Network: Building a Community of Investors

Forget cold calls and generic email blasts. Content Carnivores built a thriving online community around VCapital. They strategically grew their presence on Twitter and LinkedIn, connecting with a highly targeted audience of investors and advisors. It was like building a VIP room for the investment world, where VCapital’s message resonated with the right people.

The Stage: Showcasing Portfolio Companies

VCapital hosted leadership events, bringing together investors, industry experts, and their portfolio companies. Content Carnivores ensured these events weren’t just stuffy conferences but engaging experiences showcasing the potential of VCapital’s investments. Attendance surged, and valuable connections were forged.

The Results: Beyond the Numbers

While specific metrics remain confidential, the impact was undeniable. VCapital’s brand visibility skyrocketed, engagement with potential investors soared, and website traffic and inquiries multiplied. Most importantly, VCapital’s fund grew, attracting investors who were drawn not just to the financial returns but also to the firm’s vision and commitment to innovation.

Content Carnivores provided VCapital with more than just marketing support; they offered a strategic partnership that fueled their growth. They demonstrated that in the venture capital world, success requires more than just writing checks. It requires building a brand, fostering a community, and telling compelling stories. And that’s exactly what Content Carnivores delivered.

But what if there was a better way?

Based on years of experience and analysis of millions of social media impressions, Content Carnivores developed SPEAR, a system for science communication that keeps your message fresh, relevant, and engaging.

What is SPEAR?

SPEAR is an acronym that stands for:

• Science: Explain your research, products, and technology in a clear and compelling way. Highlight your unique value proposition and differentiate yourself from the competition.
• Press Releases: Share company news and announcements, but don’t just rely on press releases alone. Create your own “news” by highlighting interesting aspects of your work and sharing behind-the-scenes insights.
• Events: Maximize the impact of conferences and other events by building anticipation beforehand, providing live coverage during, and sharing key takeaways afterward.
• Affinity Groups: Identify and engage with relevant stakeholder groups, such as investors, patients, advocates, and industry partners. Tailor your message to resonate with their specific interests.
• Repurpose: Don’t let your content go to waste! Repurpose your best performing content across different platforms and formats.

How SPEAR Works

SPEAR is more than just a content calendar; it’s a philosophy of continuous engagement and relationship building. By focusing on the different aspects of your company and its audience, SPEAR ensures that you’re always providing valuable and interesting content.

Data-Driven Insights

We’ve developed a unique data model that analyzes patterns in social media engagement, allowing us to identify the most effective visuals, keywords, concepts, and posting times. This data-driven approach ensures that your content is optimized for maximum impact.

Visual Storytelling

Science can be complex, but that doesn’t mean it can’t be visually appealing. We use infographics, videos, and other visual elements to bring your science to life and make it more accessible to a wider audience. We also tailor visuals to resonate with different audience segments within the SPEAR framework.

Humanizing Science

We believe that science is ultimately about people. Whether it’s the researchers making groundbreaking discoveries or the patients benefiting from new treatments, we strive to humanize our content by incorporating personal stories and highlighting the real-world impact of your work.

Interactive Engagement

We encourage audience participation through interactive elements like polls, Q&A sessions, and live events. This helps to build a sense of community and keep your audience engaged.

The SPEAR Advantage

By implementing the SPEAR system, science companies can:

• Maintain a consistent and engaging social media presence
• Communicate complex scientific concepts in a clear and compelling way
• Build relationships with key stakeholders
• Maximize the impact of events and conferences
• Repurpose content for greater efficiency and reach

Ready to take your social media to the next level? Contact us today to learn more about the SPEAR method.

Many businesses struggle with this decision. Sometimes a rebranding with a new logo and color palette makes it obvious. Other times, a major shift in the company’s direction necessitates a complete overhaul. But what about those times when you’re still offering the same products or services, but your website is starting to show its age?

The 7-Second Rule

Studies show you have just 7 seconds to make a first impression online. Is your website making the most of those precious seconds? An outdated website can convey a lack of innovation, damage your brand image, and even cost you customers. Think about it: if your website looks like it’s from 2015, visitors might assume your business practices are just as outdated.

Signs Your Website Needs a Facelift:

• Visuals from the Past: Is your website stuck in a time warp with outdated fonts, colors, and imagery? Modern design trends prioritize clean lines, whitespace, and high-quality visuals.
• Mobile Mayhem: Does your website shrink and distort on smartphones? In today’s mobile-first world, a responsive design is essential.
• Content Confusion: Is your website content cluttered, confusing, or out of date? Clear, concise, and current information is key to engaging visitors.
• SEO Suffering: Are you struggling to rank in search results? An SEO audit can reveal technical issues and keyword opportunities that can boost your visibility.
• Slow Loading Speeds: Does your website take forever to load? Visitors are impatient, and slow loading times lead to high bounce rates.
• Low Conversion Rates: Are visitors leaving your website without taking action? A well-designed website guides users towards desired outcomes, whether it’s making a purchase, filling out a form, or contacting your team.

The Website as a Dynamic Tool:

Your website is more than just an online brochure. It’s a dynamic tool that should evolve with your business and the ever-changing digital landscape. Here’s how we approach website revamps to ensure they are efficient and impactful:

Our Unique Process:

1. Content Audit and Enhancement: We analyze your existing content, identify gaps, and incorporate new information to ensure it’s fresh, relevant, and engaging.
2. Competitive Analysis: We research your industry and competitors to understand current trends and best practices in website design and messaging.
3. Visual Refresh: We update your website’s look and feel with modern design elements, high-quality images, and intuitive navigation.
4. SEO Optimization: We conduct keyword research and implement on-page optimization strategies to improve your website’s visibility in search results.
5. User Experience Focus: We prioritize user experience (UX) by ensuring your website is easy to navigate, mobile-friendly, and accessible to all users.

The Benefits of a Website Revamp:

• Enhanced Brand Image: A modern website projects a professional and credible image, building trust with potential customers.
• Improved User Experience: A user-friendly website encourages visitors to explore, engage, and ultimately convert.
• Increased Traffic and Leads: SEO optimization and improved content can drive more qualified traffic to your site.
• Boosted Sales and Conversions: A well-designed website can guide visitors towards desired actions, resulting in increased sales and leads.
• Greater Customer Engagement: Fresh, relevant content and interactive features keep visitors engaged and coming back for more.

Investing in Your Online Presence

While a website revamp requires an investment of time and resources, it’s a crucial step in maintaining a strong online presence. A modern, engaging website can pay dividends in the form of increased brand awareness, customer loyalty, and ultimately, business growth.

Ready to give your website the refresh it deserves? Contact us for a free website assessment!